Workflow
Schrodinger(SDGR) - 2024 Q2 - Earnings Call Transcript
SDGRSchrodinger(SDGR)2024-08-01 04:46
Filings

Financial Data and Key Metrics Changes - Total revenue for Q2 2024 was 47.3million,comparedto47.3 million, compared to 35.2 million in Q2 2023, reflecting a year-over-year increase driven by software and drug discovery revenue [15][20] - Software revenue was 35.4millioninQ22024,upfrom35.4 million in Q2 2024, up from 29.4 million in Q2 2023, marking a 21% increase [11][12] - Drug discovery revenue increased to 11.9millioninQ22024from11.9 million in Q2 2024 from 5.8 million in the same period last year [15] - Overall gross margin improved to 66% in Q2 2024 from 39% in Q2 2023, driven by higher revenue and lower costs [17] Business Line Data and Key Metrics Changes - On-premise software revenue grew by 11.5% to 18.8million,whilehostedsoftwarerevenuesurgedby8218.8 million, while hosted software revenue surged by 82% to 8 million [12] - Maintenance revenue remained flat year-over-year at 5.8million,andprofessionalservicesrevenueincreasedby235.8 million, and professional services revenue increased by 23% [12] - The shift in employee allocation from collaboration projects to proprietary research contributed to a significant decrease in drug discovery service costs to 8.8 million from 14.7million[16]MarketDataandKeyMetricsChanges−ThecompanynotedchallengesintheChinesemarketduetoreducedcapitalavailabilityforbiopharmaresearch,whilegrowthopportunitieswereobservedinEuropeandNorthAmerica[14]−Thecompanymaintaineditsrevenueguidanceforthefullyear,indicatingconfidenceinthegrowthpotentialdespitemarketvolatility[10][22]CompanyStrategyandDevelopmentDirection−Thecompanyisfocusedonscalingupitssoftwarebusinessandadvancingitsdrugdiscoveryprograms,withanewinitiativeaimedatpredictivetoxicologyfundedbya14.7 million [16] Market Data and Key Metrics Changes - The company noted challenges in the Chinese market due to reduced capital availability for biopharma research, while growth opportunities were observed in Europe and North America [14] - The company maintained its revenue guidance for the full year, indicating confidence in the growth potential despite market volatility [10][22] Company Strategy and Development Direction - The company is focused on scaling up its software business and advancing its drug discovery programs, with a new initiative aimed at predictive toxicology funded by a 10 million grant from the Gates Foundation [8][22] - Collaborations with partner companies are seen as crucial for validation and capital, with recent successes including Morphic Therapeutic's planned acquisition by Lilly for 3.2billion[7][24]−Thecompanyaimstoleverageadvancedcomputationalmethodsandmachinelearningtoenhancedrugdiscoveryefficiency[8][29]Management′sCommentsonOperatingEnvironmentandFutureOutlook−Managementexpressedconfidenceincustomerretentionandscalingupsoftwareusage,particularlyinQ4,whichistypicallythelargestquarterforrenewals[32][34]−Thecompanyanticipatesthatthepredictivetoxicologyprojectwillcontributetosoftwarerevenuegrowthinthecomingyears,despiteamodestnegativeimpactongrossmarginsduringthegrantperiod[22][23]−Managementhighlightedtheimportanceofmaintainingastrongcashpositionandexploringpartnershipopportunitiestosupportongoingoperations[35]OtherImportantInformation−Thecompanyreportedalosspershareof3.2 billion [7][24] - The company aims to leverage advanced computational methods and machine learning to enhance drug discovery efficiency [8][29] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in customer retention and scaling up software usage, particularly in Q4, which is typically the largest quarter for renewals [32][34] - The company anticipates that the predictive toxicology project will contribute to software revenue growth in the coming years, despite a modest negative impact on gross margins during the grant period [22][23] - Management highlighted the importance of maintaining a strong cash position and exploring partnership opportunities to support ongoing operations [35] Other Important Information - The company reported a loss per share of 0.74 for Q2 2024, compared to net income of 4.3millioninQ22023[20]−Theaveragefullydilutedsharecountdecreasedto72.7millionfrom75.1millionyear−over−year[21]−Thecompanyexpectstoreceive4.3 million in Q2 2023 [20] - The average fully diluted share count decreased to 72.7 million from 75.1 million year-over-year [21] - The company expects to receive 48 million from the sale of its holding in Morphic, which will help offset cash used in operations [21] Q&A Session Summary Question: Outlook for the rest of the year and customer dynamics - Management noted strong engagement with customers and high retention rates, with expectations for scaling up usage primarily in Q4 [32][34] Question: Cash position and options for capital - Management highlighted the expected cash inflow from Morphic and ongoing discussions for potential partnerships as sources of capital [35] Question: Growth in software business among smaller biotech companies - Despite a turbulent environment, new biotech companies are still forming and seeking cost-effective solutions, leading to more new accounts than reductions [37] Question: Launch timeline for predictive toxicology tools - The company is excited about the project and expects to release it in the near future, contributing to software revenue growth [40][41] Question: Clinical trial enrollment and timeline changes - Enrollment is progressing well, and the timeline for data readouts has been refined to provide more specific guidance [45][46] Question: Impact of large-scale customer discussions on revenue - Management indicated that discussions with large customers could lead to both immediate and long-term revenue growth opportunities [47][48]